Alternative Application Methods of Pre-procedural Povidone Iodine Mouthrinse
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wimonrach Sriudom
- Phone Number: +66840281415
- Email: wimonrach.sri@gmail.com
Study Contact Backup
- Name: Wannakorn Sriarj
- Phone Number: +6622188906
- Email: Wannakorn.S@chula.ac.th
Study Locations
-
-
-
Bangkok, Thailand
- Faculty of Dentistry, Chulalongkorn University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Thai people
- no underlying disease, no pregnant
- at least 24 teeth
- No use iodine gargle
- No allergy to iodine and seafood
- No orthodontic and prosthetic treatment
- No ulcer and edentulous area
- Saliva flow rate in male (0.57+-0.3 ml/minute), in woman (0.41+-0.27 ml/minute)
- PI score lower than 0.6 (Green and vermillion index)
Exclusion Criteria:
- treatment orthodontic or prosthetic treatment currently
- Allergy to iodine between reach
- Can not participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Gargle method
the participant will use 0.2% iodine gargle with gargle method by hold in mouth 30 second and gargle 30 seconds after that spit out
|
Iodine gargle 0.2 %
|
|
Experimental: Swab method
the participant will use 0.2 iodine gargle with swab method by the researcher apply on mouth 1 minute without spit out
|
Iodine gargle 0.2 %
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The rate of retention of iodine in saliva
Time Frame: 0, 5, 10, 20, 30, 60 and 120 minutes
|
The retention of iodine in saliva after get the gargle (show in percentage)
|
0, 5, 10, 20, 30, 60 and 120 minutes
|
|
The comparison of the retention of iodine between gargle and swab
Time Frame: 0, 5, 10, 20, 30, 60 and 120 minutes
|
The comparison of rate of retention of iodine in saliva between gargle and swab (show in percentage)
|
0, 5, 10, 20, 30, 60 and 120 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Wannakorn Sriar, Faculty of Dentistry, Chulalongkorn University
Publications and helpful links
General Publications
- To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, Leung WS, Chik TS, Choi CY, Kandamby DH, Lung DC, Tam AR, Poon RW, Fung AY, Hung IF, Cheng VC, Chan JF, Yuen KY. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis. 2020 Jul 28;71(15):841-843. doi: 10.1093/cid/ciaa149.
- Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x.
- Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Apr;14(2):185-192. doi: 10.1007/s11684-020-0754-0. Epub 2020 Mar 12.
- Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens. Infect Dis Ther. 2018 Jun;7(2):249-259. doi: 10.1007/s40121-018-0200-7. Epub 2018 Apr 9.
- Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. Int J Oral Sci. 2020 Mar 3;12(1):9. doi: 10.1038/s41368-020-0075-9.
- Ge ZY, Yang LM, Xia JJ, Fu XH, Zhang YZ. Possible aerosol transmission of COVID-19 and special precautions in dentistry. J Zhejiang Univ Sci B. 2020 May;21(5):361-368. doi: 10.1631/jzus.B2010010. Epub 2020 Mar 16.
- Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar;19(3):141-154. doi: 10.1038/s41579-020-00459-7. Epub 2020 Oct 6. Erratum In: Nat Rev Microbiol. 2022 May;20(5):315.
- Cochran MA, Miller CH, Sheldrake MA. The efficacy of the rubber dam as a barrier to the spread of microorganisms during dental treatment. J Am Dent Assoc. 1989 Jul;119(1):141-4. doi: 10.14219/jada.archive.1989.0131.
- Ather A, Patel B, Ruparel NB, Diogenes A, Hargreaves KM. Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care. J Endod. 2020 May;46(5):584-595. doi: 10.1016/j.joen.2020.03.008. Epub 2020 Apr 6.
- Kariwa H, Fujii N, Takashima I. Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions and chemical reagents. Dermatology. 2006;212 Suppl 1(Suppl 1):119-23. doi: 10.1159/000089211.
- Tabatabaeizadeh SA. Airborne transmission of COVID-19 and the role of face mask to prevent it: a systematic review and meta-analysis. Eur J Med Res. 2021 Jan 2;26(1):1. doi: 10.1186/s40001-020-00475-6.
- Chen L, Zhao J, Peng J, Li X, Deng X, Geng Z, Shen Z, Guo F, Zhang Q, Jin Y, Wang L, Wang S. Detection of SARS-CoV-2 in saliva and characterization of oral symptoms in COVID-19 patients. Cell Prolif. 2020 Dec;53(12):e12923. doi: 10.1111/cpr.12923. Epub 2020 Oct 19.
- Okui T, Matsuda Y, Karino M, Hideshima K, Kanno T. Oral Mucosa Could Be an Infectious Target of SARS-CoV-2. Healthcare (Basel). 2021 Aug 19;9(8):1068. doi: 10.3390/healthcare9081068.
- Lippi G, Mattiuzzi C, Bovo C, Plebani M. Current laboratory diagnostics of coronavirus disease 2019 (COVID-19). Acta Biomed. 2020 May 11;91(2):137-145. doi: 10.23750/abm.v91i2.9548.
- Jamal M, Shah M, Almarzooqi SH, Aber H, Khawaja S, El Abed R, Alkhatib Z, Samaranayake LP. Overview of transnational recommendations for COVID-19 transmission control in dental care settings. Oral Dis. 2021 Apr;27 Suppl 3(Suppl 3):655-664. doi: 10.1111/odi.13431. Epub 2020 Jun 3.
- Samaranayake LP, Reid J, Evans D. The efficacy of rubber dam isolation in reducing atmospheric bacterial contamination. ASDC J Dent Child. 1989 Nov-Dec;56(6):442-4.
- Samaranayake LP, Peiris M. Severe acute respiratory syndrome and dentistry: a retrospective view. J Am Dent Assoc. 2004 Sep;135(9):1292-302. doi: 10.14219/jada.archive.2004.0405.
- Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses. J Prosthodont. 2020 Aug;29(7):599-603. doi: 10.1111/jopr.13220. Epub 2020 Jul 24.
- Martinez Lamas L, Diz Dios P, Perez Rodriguez MT, Del Campo Perez V, Cabrera Alvargonzalez JJ, Lopez Dominguez AM, Fernandez Feijoo J, Diniz Freitas M, Limeres Posse J. Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2022 Apr;28 Suppl 1(Suppl 1):908-911. doi: 10.1111/odi.13526. Epub 2020 Jul 29. No abstract available.
- Reis INR, do Amaral GCLS, Mendoza AAH, das Gracas YT, Mendes-Correa MC, Romito GA, Pannuti CM. Can preprocedural mouthrinses reduce SARS-CoV-2 load in dental aerosols? Med Hypotheses. 2021 Jan;146:110436. doi: 10.1016/j.mehy.2020.110436. Epub 2020 Nov 27.
- Rattanawiboon C, Chaweewannakorn C, Saisakphong T, Kasevayuth K, Trairatvorakul C. Effective Fluoride Mouthwash Delivery Methods as an Alternative to Rinsing. Nurs Res. 2016 Jan-Feb;65(1):68-75. doi: 10.1097/NNR.0000000000000131.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HREC-DCU 2023-074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.